FDA/CDC

Teva expands its recall of losartan lots


 

The Food and Drug Administration has announced that Teva is expanding its recall to certain lots of losartan potassium distributed by Golden State Medical Supply, according to a release.

FDA icon

The recall for this and other angiotensin II receptor blockers was initiated by Teva on April 25, 2019, because of detection of unacceptable levels of the possibly cancer-causing impurity N-Nitroso-N-methyl-4-aminobutyric acid (NMBA). Teva expanded this recall on June 10, with another update issued on June 12.

Losartan is not the only ARB found to contain NMBA; a full list of all ARBs affected can be found on the FDA website and currently includes more than 1,100 lots being recalled. The list can be searched and sorted by such considerations as medicine in question, company involved, and lot number.

Next Article: